Meeting
2014 ASCO Annual Meeting
Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2:HER3 heterodimer.
Authors
Cecile Geuijen
Merus, Utrecht, Netherlands
Cecile Geuijen , Eric Rovers , Roy Nijhuis , Renate den Blanken-Smit , Therese Visser , Willem Bartelink , Arjen Kramer , Vanessa Zondag-van der Zande , Carina Clements , Linda Kaldenberg , Nellie Nieuwenhuizen , Pieter Fokko van Loo , Rob Roovers , Tristan Gallenne , Leo Price , Setareh Van Driel Shamsili , Lex Bakker , Ton Logtenberg , John de Kruif , Mark Throsby
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 560)
DOI
10.1200/jco.2014.32.15_suppl.560
Abstract #
560
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.
First Author: Erika Paige Hamilton
Poster
2016 Gastrointestinal Cancers Symposium
Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer.
First Author: Ron Bose
Poster
2013 ASCO Annual Meeting
Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).
First Author: Silvia Marsoni
Poster
2023 ASCO Annual Meeting
Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers.
First Author: Ryul Kim